Uncategorized

Atorvastatin Calcium (generic Lipitor) is on its way!

Beginning tomorrow, Pfizer’s blockbuster treatment for high cholesterol comes off patent paving the way for less expensive generics.  The generic name for Lipitor is Atorvastatin Calcium and it presents another option for dispensing clinics to better serve their patients.  How big a deal is this?  There are currently 8.7 million Americans taking Lipitor.  Lipitor has been on the market since 1997.  Pfizer sold $10.7 billion of this drug last year.

Wholesale pharmaceutical distributors like Northwind Pharmaceuticals will have Atorvastatin Calcium available beginning Wednesday, November 30.  For the first 180 days, rules limiting generic competition will limit price decreases but significant price decreases should hit after that point.  Drug plans as well as Pfizer are offering incentives to stay with Lipitor or switch but it is difficult to say how long those incentives will be offered.  For physicians offering office medication dispensing, it is interesting to note that the average co-pay for Lipitor is $49 and the average co-pay for generic medications is $10.

As prices come down, Northwind will offer prepackaged versions of Atorvastatin Calcium to make it easier to dispense within clinics.  For more information on the change, check out this article in today’s Wall Street Journal.

Schedule a free claims analysis now.

Let’s Talk now

Healthcare Storm 2025: What Will It Be?

Phillip Berry | Jan 1st, 2025
When it comes to American healthcare, we’ve become really good at highlighting its failings. Watching the flurry of lamentations, frustrations, denigrations, and prognostications, over the last few weeks, would lead any rational person to believe that nothing is working in our healthcare system. And, not only is it “not working,” many people conclude that it … more »

continue reading

New Drugs to Market – October Update

Phillip Berry | Oct 25th, 2024
The Food and Drug Administration (FDA) approved three novel drug therapies in October. One of those therapies,  Hympavzi (marstacimab-hncq), is a medication indicated for the treatment of patients with Hemophilia A and Hemophilia B. Hympavzi utilizes a new pathway to help reduce the risk of bleeding episodes in patients with Hemophilia, a disease that impacts … more »

continue reading

Letter From a Pharmacist – On Pharmacy Closures

Phillip Berry | Oct 25th, 2024
Pharmacists have a time-honored role as an integral contributor to the delivery of health care. From the earliest apothecaries to the retail stores of today, community pharmacists have provided guidance about health, wellness and medication therapy. Their expertise ranges from preventive care to the most advanced medications used in the treatment of complex disease.  Despite … more »

continue reading